McCann Joe's most recent trade in POINT Biopharma Global Inc was a trade of 3,494,153 Common Stock done . Disclosure was reported to the exchange on Dec. 22, 2023.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
POINT Biopharma Global Inc | McCann Joe | Director, Chief Executive Officer | 22 Dec 2023 | 3,494,153 | 0 | - | - | Common Stock | ||
POINT Biopharma Global Inc | Joe McCann | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Dec 2023 | 692,643 | 0 | - | - | Stock Option (Right to Buy) | |
POINT Biopharma Global Inc | McCann Joe | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Dec 2023 | 381,795 | 0 | - | - | Stock Option (Right to Buy) | |
POINT Biopharma Global Inc | McCann Joe | Director, Chief Executive Officer | 22 Dec 2023 | 2,160 | 0 | - | - | Common Stock | ||
POINT Biopharma Global Inc | Joe McCann | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2023 | 692,643 | 692,643 | - | - | Stock Option (Right to Buy) | |
POINT Biopharma Global Inc | Joe McCann | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 6.64 per share. | 29 Nov 2022 | 2,160 | 3,616,313 | - | 6.6 | 14,342 | Common Stock |
POINT Biopharma Global Inc | Joe McCann | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2022 | 381,795 | 381,795 | - | - | Stock Option (Right to Buy) |